Transcript
A (0:00)
This podcast is brought to you by Dynatrace, the leader in AI Powered Observability. With analytics, automation and next level intelligence on one unified platform, Dynatrace delivers the visibility and real time insights you need to deliver better, more secure software, successful AI initiatives and innovation at the speed of business. Turn data into decisions that drive your business forward with AI powered Observability where it counts. Learn more@dynatrace.com WSJ that's www. N a T-R-A c e.com WSJ.
B (0:34)
The government shutdown nears a record as the longest in US History plus what an ominous milestone for a famous method of valuing stocks tells us about what's next for markets.
C (0:45)
It's proven to be an extremely reliable indicator of what to expect in the several years ahead of us.
B (0:51)
And former Vice President Dick Cheney, an architect of the US war on terror, has died at 84. It's Tuesday, November 4, March Sarai I'm Sabrina Siddiqui for the Wall Street Journal, sitting in for Alex Osla. This is the PM edition of what's news, the top headlines and business stories that move the world today. The Trump administration is negotiating with Eli Lilly and Novo Nordisk to offer their blockbuster weight loss drugs at lower prices, as low as $149 for a month's supply through a Trump branded government website for buying medications. People familiar with the matter say the proposed agreements would also mean Medicare and Medicaid coverage of expensive obesity drugs like Wegovy and Zepbound. Medicare drug benefit plans today can cover the weight loss drugs, just not only for losing weight, for example, they're available for reducing risk of heart attacks or sleep apnea, and few states offer Medicaid coverage for the drugs for weight loss. And that's not the only news today about the weight loss drug market. There is a new twist in the high stakes bidding war for the obesity drug developer mtsera, as Novo Nordisk and Pfizer have both raised their offers for the company. Metsera said today that Novo Nordisk's proposal values the company at approximately $10 billion, up from its previous bid of $9 billion. Pfizer, which had struck a deal to buy Mitcera for up to $7.3 billion in September, is now offering about $8.1 billion. Novo Nordisk's effort to buy Mitcera has touched off a legal battle with Pfizer. The fight over the three year old company, which has no approved drugs, highlights how valuable the weight loss drug business has become. A Famous measure for valuing US Stocks has crossed a big milestone that points to some trouble ahead. That measure is a calculation of stocks price to earnings ratio by Nobel Prize winning economist Robert Shiller. It takes a decade's worth of corporate earnings and adjusts them for inflation. And it topped 40 last month for the second time ever. The only other time it reached this level was in 1999, the peak of the tech stock bubble. Spencer Jacob, who writes the Wall Street Journal's Markets AM newsletter, joins us now to discuss. Spencer, explain this measure to us. Why is it important to investors?
